<p>In this informative episode, Dr. Jennie Berkovich is joined by experienced neurologists Dr. Palma and Dr. Lewis, Executive Medical Directors at Eli Lilly and Company. Our guests take this opportunity to share their expert opinion and scientific understanding of Parkinson’s disease and how we can anticipate medical interventions changing — possibly within our lifetimes. </p><p>We explore how our genes, and genetic variants, can influence the onset, symptoms, and severity of Parkinson’s disease. We address when genetic testing can be most helpful, who might be at higher risk, and how these discoveries are leading to potential new treatments and personalized care. </p><p>Dr. Alberto Palma is Executive Medical Director, Early-Phase Development, Neurodegeneration Programs Lead at Eli Lilly and Company.</p><p>Dr. Travis Lewis is Executive Medical Director at the Institute for Genetic Medicine at Eli Lilly and Company.</p><p>Both are actively working on gene therapy clinical trials that aim to slow the progression of Parkinson’s and its symptoms. </p><p>DISCLAIMER: This video is sponsored by Eli Lilly and Company and hosted by JOWMA. It is intended for educational purposes only. The content in this video reflects treatment practices in the U.S.; please refer to your local guidelines for more information.</p><p>Sponsor the JOWMA Podcast! Email
[email protected] </p><p>Become a JOWMA Member! www.jowma.org </p><p>Follow us on Instagram! www.instagram.com/JOWMA_org </p><p>Follow us on Twitter! www.twitter.com/JOWMA_med </p><p>Follow us on Facebook! https://www.facebook.com/jowmaorg </p><p><br>Stay up to date with JOWMA news! Sign up for the JOWMA newsletter! <a href="https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e"><u>https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e</u></a> </p>
